There was no statistically significant difference between the pazopanib/pemetrexed and cisplatin/pemetrexed arms for PFS ( median PFS , @ versus @ weeks , respectively ; hazard ratio = @ ; @ % confidence interval , @ % -@ % ; p = @ ) or objective response rate ( @ % versus @ % , respectively ; @ % confidence interval , -@ % to @ % ; p = @ ) .